Member Exclusive
Spotlight on immunotherapy, Spotlight on commercialization and translation, Spotlight on cell therapy regulation, Cell therapy, Latest news & views, Industry developments, Manufacturing & scale-up
Why the FDA’s CAR-T approval sends strong signal to cell therapy industry: an interview with Martin Lamb
In this interview, Martin Lamb, TrakCel, discusses the recent FDA approval of Novartis’ CAR-T cell therapy.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
- Connect and collaborate with other members
- Post about your own research, share your take on key topics and more
No comments yet.